← All trials
NCT06083623
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 6, 2023
- Primary completion
- May 31, 2026
- Completion date
- Aug 31, 2026
- First posted
- Oct 16, 2023
- Last posted
- Oct 16, 2023
- Enrollment
- 2250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Trinomab Biotech Co., Ltd.Lead sponsor
- Chongqing Medical UniversityOverall official - principal investigator
- Guangzhou Trinomab Biotech Co., Ltd.Study director
- Guangzhou Trinomab Biotech Co., Ltd.Official
- Sichuan UniversityOfficial
- Chongqing Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.